Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
RESMED INC
Report date May 04, 2026 · Filed May 04, 2026
Section 16 reporting ended · disclosed 2026-05-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| ResMed Common StockSEC Table I · non-derivative | Direct | 83,495 |
Reported balance
Holding disclosure · report date 2026-05-04 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 83,495 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 18, 2021 Filed Jan 20, 2021 00:57 UTC | RESMED INC RMD · Entity 2692 | GrantResMed Common Stock | 1,822 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-002064 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,422 F1 · shares: Represents performance-based restricted stock units granted on November 21, 2019. The shares were earned on January 18, 2021, when the compensation committee certified that the performance metrics were met for this portion of the grant. The earned units remain subject to time-vesting requirements, and are scheduled to vest on the three-year anniversary of the grant, assuming continued service through the vesting date. Read SEC document |
| January 11, 2021 Filed Jan 12, 2021 21:11 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 2,500 | $218.70 | $546,750.00 |
DisclosureSEC source: 0001127602-21-001481 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,600 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| December 10, 2020 Filed Dec 14, 2020 17:43 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 2,500 | $211.06 | $527,650.00 |
DisclosureSEC source: 0001127602-20-031237 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,100 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| November 24, 2020 Filed Nov 25, 2020 23:01 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 5,000 | $211.00 | $1,055,000.00 |
DisclosureSEC source: 0001127602-20-030034 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,600 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| November 17, 2020 Filed Nov 20, 2020 00:20 UTC | RESMED INC RMD · Entity 2692 | GrantResMed Common Stock | 26,246 | $214.74 | $5,636,066.04 |
DisclosureSEC source: 0001127602-20-029625 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,600 F1 · kind: Represents performance-based restricted stock units granted on November 16, 2017. The shares were earned on November 17, 2020, when the compensation committee certified that the performance metrics were met. F2 · balance_after: Includes 78.73 shares of ResMed stock purchased on October 31, 2020, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| October 15, 2020 Filed Oct 19, 2020 21:20 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 2,500 | $176.72 | $441,800.00 |
DisclosureSEC source: 0001127602-20-027222 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,275 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| September 15, 2020 Filed Sep 16, 2020 22:35 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 2,500 | $175.49 | $438,725.00 |
DisclosureSEC source: 0001127602-20-025254 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,775 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| August 17, 2020 Filed Aug 19, 2020 16:34 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 2,500 | $177.55 | $443,875.00 |
DisclosureSEC source: 0001127602-20-023863 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,275 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| August 13, 2020 Filed Aug 17, 2020 15:47 UTC | RESMED INC RMD · Entity 2692 | GrantResMed Common Stock | 6,979 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-023640 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,775 F1 · kind: Represents performance-based restricted stock units granted on November 21, 2019. The shares were earned on August 13, 2020, when the compensation committee certified that the performance metrics were met. Stock units vest 1/3 each year on the anniversary of the grant. Read SEC document |
| July 15, 2020 Filed Jul 18, 2020 01:26 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 2,500 | $196.98 | $492,450.00 |
DisclosureSEC source: 0001127602-20-021787 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,796 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| June 15, 2020 Filed Jun 16, 2020 23:43 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 2,500 | $158.79 | $396,975.00 |
DisclosureSEC source: 0001127602-20-019804 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,296 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| May 15, 2020 Filed May 19, 2020 14:17 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 2,500 | $162.05 | $405,125.00 |
DisclosureSEC source: 0001127602-20-017051 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,796 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · balance_after: Includes 84.6316 shares of ResMed stock purchased on April 30, 2020, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| April 15, 2020 Filed Apr 16, 2020 23:00 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 2,500 | $159.03 | $397,575.00 |
DisclosureSEC source: 0001127602-20-013947 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,211 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| March 16, 2020 Filed Mar 17, 2020 21:18 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 2,500 | $137.49 | $343,725.00 |
DisclosureSEC source: 0001127602-20-011112 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,711 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 19:32 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 2,500 | $176.14 | $440,350.00 |
DisclosureSEC source: 0001127602-20-006323 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,211 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| January 15, 2020 Filed Jan 18, 2020 00:37 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 2,500 | $158.43 | $396,075.00 |
DisclosureSEC source: 0001127602-20-001962 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,711 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| December 16, 2019 Filed Dec 18, 2019 17:41 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 2,500 | $154.71 | $386,775.00 |
DisclosureSEC source: 0001127602-19-035343 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,211 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| November 26, 2019 Filed Nov 28, 2019 00:55 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 2,500 | $147.00 | $367,500.00 |
DisclosureSEC source: 0001127602-19-033849 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,711 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| November 21, 2019 Filed Nov 22, 2019 21:15 UTC | RESMED INC RMD · Entity 2692 | GrantResMed Common Stock | 34,408 | $146.34 | $5,035,266.72 |
DisclosureSEC source: 0001127602-19-033573 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,211 F1 · kind: Represents performance-based restricted stock units granted on November 16, 2016. The shares were earned on November 21, 2019, when the compensation committee certified that the performance metrics were met. Read SEC document |
| October 30, 2019 Filed Nov 1, 2019 18:01 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 3,000 | $145.95 | $437,850.00 |
DisclosureSEC source: 0001127602-19-031439 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,690 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| October 24, 2019 Filed Oct 25, 2019 20:04 UTC | RESMED INC RMD · Entity 2692 | GrantResMed Common Stock | 2,545 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-031064 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,690 F1 · shares: Represents performance-based restricted stock units granted on November 14, 2018. The shares were earned on October 24, 2019, when the compensation committee certified that the performance metrics were met for this portion of the grant. The earned units remain subject to time-vesting requirements, and are scheduled to vest on the three-year anniversary of the grant, assuming continued service through the vesting date. Read SEC document |
| September 30, 2019 Filed Oct 2, 2019 16:22 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 3,000 | $134.14 | $402,420.00 |
DisclosureSEC source: 0001127602-19-029591 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,145 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| August 30, 2019 Filed Sep 3, 2019 15:53 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 3,000 | $139.21 | $417,630.00 |
DisclosureSEC source: 0001127602-19-027676 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,145 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| August 14, 2019 Filed Aug 15, 2019 01:16 UTC | RESMED INC RMD · Entity 2692 | GrantResMed Common Stock | 5,139 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-026659 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,145 F1 · shares: Represents performance-based restricted stock units granted on November 14, 2018. The shares were earned on August 14, 2019, when the compensation committee certified that the performance metrics were met. Stock units vest 1/3 each year on the anniversary of the grant. Read SEC document |
| July 30, 2019 Filed Jul 31, 2019 22:45 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 3,000 | $129.14 | $387,420.00 |
DisclosureSEC source: 0001127602-19-025568 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,006 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · balance_after: Corrects misstatement of 492 certified RSUs that should have been included on the October 26, 2018 report. Read SEC document |
| July 01, 2019 Filed Jul 2, 2019 23:32 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 3,000 | $123.17 | $369,510.00 |
DisclosureSEC source: 0001127602-19-023788 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,514 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| May 30, 2019 Filed Jun 3, 2019 15:46 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 3,000 | $112.34 | $337,020.00 |
DisclosureSEC source: 0001127602-19-020402 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,514 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · balance_after: Includes 124.66 shares of ResMed stock purchased on April 30, 2019, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| April 30, 2019 Filed May 1, 2019 22:13 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 3,000 | $102.98 | $308,940.00 |
DisclosureSEC source: 0001127602-19-016793 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,390 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 15:53 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 3,000 | $104.96 | $314,880.00 |
DisclosureSEC source: 0001127602-19-014410 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,390 F1 · kind: The transaction was conducted under a Rule 10b5-1 Plan. Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 15:05 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 3,000 | $103.00 | $309,000.00 |
DisclosureSEC source: 0001567619-19-005878 · doc1.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,390 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| January 30, 2019 Filed Feb 1, 2019 00:12 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 3,000 | $92.30 | $276,900.00 |
DisclosureSEC source: 0001567619-19-002059 · doc1.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,390 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| January 15, 2019 Filed Jan 16, 2019 21:18 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 2,000 | $114.18 | $228,360.00 |
DisclosureSEC source: 0001567619-19-001237 · doc1.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,390 F1 · kind: The transaction was conducted under a Rule 10b5-1 Plan. F1 · shares: The transaction was conducted under a Rule 10b5-1 Plan. Read SEC document |
| December 31, 2018 Filed Jan 2, 2019 22:56 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 3,000 | $112.50 | $337,500.00 |
DisclosureSEC source: 0001567619-19-000132 · doc1.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,390 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| December 17, 2018 Filed Dec 20, 2018 18:38 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 2,000 | $112.56 | $225,120.00 |
DisclosureSEC source: 0001567619-18-008415 · doc1.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,390 F1 · kind: The transaction was conducted under a Rule 10b5-1 Plan. F1 · shares: The transaction was conducted under a Rule 10b5-1 Plan. Read SEC document |
| November 30, 2018 Filed Dec 3, 2018 17:09 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 3,000 | $110.50 | $331,500.00 |
DisclosureSEC source: 0001567619-18-007211 · doc1.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,390 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| November 21, 2018 Filed Nov 26, 2018 21:39 UTC | RESMED INC RMD · Entity 2692 | GrantResMed Common Stock | 32,234 | $104.18 | $3,358,138.12 |
DisclosureSEC source: 0001567619-18-006927 · doc1.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,390 F1 · kind: Represents performance-based restricted stock units granted on November 19, 2015. The shares were earned on November 21, 2018, when the compensation committee certified that the performance metrics were met. F1 · shares: Represents performance-based restricted stock units granted on November 19, 2015. The shares were earned on November 21, 2018, when the compensation committee certified that the performance metrics were met. Read SEC document |
| November 15, 2018 Filed Nov 17, 2018 01:50 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 2,000 | $101.44 | $202,880.00 |
DisclosureSEC source: 0001567619-18-006573 · doc1.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,156 F1 · kind: The transaction was conducted under a Rule 10b5-1 Plan. F2 · balance_after: Includes 134.30 shares of ResMed stock purchased on October 31, 2018, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| November 14, 2018 Filed Nov 17, 2018 01:50 UTC | RESMED INC RMD · Entity 2692 | GrantResMed Common Stock Options · Derivative | 22,883 | $0.00 Strike: $101.64 | $0.00 |
DisclosureSEC source: 0001567619-18-006573 · doc1.xml · derivative · entry 2 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,883 Underlying: ResMed Common Stock · 22,883 shares Expires 2025-11-14 F3 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 annually each November 11, 2019, 2020 and 2021. Read SEC document |
| October 29, 2018 Filed Oct 30, 2018 21:52 UTC | RESMED INC RMD · Entity 2692 | GrantResMed Common Stock | 2,789 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-18-004795 · doc1.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,021 F1 · shares: Represents performance-based restricted stock units granted on November 16, 2017. The shares were earned on October 29, 2018, when the compensation committee certified that the performance metrics were met. The earned units remain subject to time-vesting requirements, and are scheduled to vest on the three-year anniversary of the grant, assuming continued service through the vesting date. Read SEC document |
| October 15, 2018 Filed Oct 17, 2018 17:09 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 2,000 | $103.16 | $206,320.00 |
DisclosureSEC source: 0001567619-18-004215 · doc1.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,232 F1 · kind: The transaction was conducted under a Rule 10b5-1 Plan. Read SEC document |
| September 17, 2018 Filed Sep 18, 2018 23:13 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 2,000 | $114.30 | $228,600.00 |
DisclosureSEC source: 0001567619-18-002849 · doc1.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,232 F1 · kind: The transaction was conducted under a Rule 10b5-1 Plan. Read SEC document |
| August 15, 2018 Filed Aug 16, 2018 23:11 UTC | RESMED INC RMD · Entity 2692 | GrantResMed Common Stock | 12,160 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-18-001318 · doc1.xml · nonDerivative · entry 2 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,232 F2 · shares: Represents performance-based restricted stock units granted on November 16, 2017. The shares were earned on August 15, 2018, when the compensation committee certified that the performance metrics were met. Read SEC document |
| August 15, 2018 Filed Aug 16, 2018 23:11 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 2,000 | $107.45 | $214,900.00 |
DisclosureSEC source: 0001567619-18-001318 · doc1.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,072 F1 · kind: The transaction was conducted under a Rule 10b5-1 Plan. Read SEC document |
| July 16, 2018 Filed Jul 17, 2018 18:05 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 2,000 | $109.01 | $218,020.00 |
DisclosureSEC source: 0001140361-18-032693 · doc1.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,072 F1 · kind: The transaction was conducted under a Rule 10b5-1 Plan. Read SEC document |
| June 15, 2018 Filed Jun 19, 2018 22:42 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 2,000 | $106.76 | $213,520.00 |
DisclosureSEC source: 0001140361-18-029197 · doc1.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,072 F1 · kind: The transaction was conducted under a Rule 10b5-1 Plan. Read SEC document |
| May 15, 2018 Filed May 17, 2018 00:47 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 2,000 | $101.52 | $203,040.00 |
DisclosureSEC source: 0001140361-18-024284 · doc1.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,072 F1 · kind: The transaction was conducted under a Rule 10b5-1 Plan. Read SEC document |
| April 16, 2018 Filed Apr 18, 2018 01:37 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 2,000 | $99.36 | $198,720.00 |
DisclosureSEC source: 0001140361-18-018865 · doc1.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,072 F1 · kind: The transaction was conducted under a Rule 10b5-1 Plan. Read SEC document |
| March 15, 2018 Filed Mar 19, 2018 16:38 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 2,000 | $98.53 | $197,060.00 |
DisclosureSEC source: 0001140361-18-013972 · doc1.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,072 F1 · kind: The transaction was conducted under a Rule 10b5-1 Plan. Read SEC document |
| February 15, 2018 Filed Feb 17, 2018 01:27 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 2,000 | $93.42 | $186,840.00 |
DisclosureSEC source: 0001140361-18-008882 · doc1.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,072 F1 · kind: The transaction was conducted under a Rule 10b5-1 Plan. Read SEC document |
| February 01, 2018 Filed Feb 2, 2018 22:16 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 1,250 | $100.13 | $125,162.50 |
DisclosureSEC source: 0001140361-18-004816 · doc1.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,072 F1 · kind: The transaction was conducted under a Rule 10b5-1 Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.